GBS Venture Partners

Founded in 1996, GBS invests in young businesses developing and commercialising products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for our investors. Our areas of particular interest and expertise include human healthcare, biotechnology product development and life science start-ups. In particular, recent investments have included biological or small molecule therapeutics, medical devices and diagnostics.

For more information on GBS Venture Partners please visit:
www.gbsventures.com.au.

Brandon Capital Partners

Brandon Capital Partners was founded in 2007 and makes seed and venture capital investments into emerging businesses in the high-growth life science industry. In addition to capital, Brandon enables entrepreneurs to access the resources needed to build successful businesses. We approach each investment as a collaborative alliance. Brandon’s team has a track record of successful life science investment as well as a history of working in research, operations and business development in the life sciences industry.

For more information on Brandon Capital Partners please visit:
www.brandoncapital.com.au.

BizCapital Pty Ltd

bizCapital is the investment fund of ATP Innovations – Australia’s leading business incubator. ATP Innovations has a portfolio of over 50 companies in the life sciences, engineering and information technology sectors. The company is based at the Australian Technology Park, delivering value to early-stage companies and accelerating their path to success. ATP Innovations is owned by four of Australia's premier universities – the University of Sydney, the University of New South Wales, the Australian National University and the University of Technology, Sydney.

For more information on bizCapital and ATP Innovations please visit:
www.atp-innovations.com.

In addition to the above private investment Elastagen has also received significant support from programs managed by both the NSW State government (NSW Biobusiness, DSRD) and Australian Federal government (NCRIS, R&D tax offset and Export Market Development).